| Title | Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab (MATCH Study) |
|---|---|
| Disease/Condition | Pediatric Hematology/Oncology,Cancer,Lymphoma,Lymphatic and Spleen Diseases,Epstein-Barr Virus (EBV),Lymphoproliferative Disorders,Immune System Diseases |
| Description | |
| Eligibility Criteria | Click here for eligibility requirements |
| Principal Investigator | David Loeb, MD |
| Contact Name | Elodie Benard |
| Contact Email | ebenard@montefiore.org |
| Protocol Number | 16-10-211-01 |
| Inclusion/Notes | This Information was obtained from ClinicalTrials.gov |
| Status | Active/Enrolling |
| Adult Clinical Trial | No |
| Pediatric Clinical Trial | Yes |
| Sub-Specialty | Pediatric Hematologic Oncology - post transplant cancer |
| Adult, Pediatric, Both | Pediatric |